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Although the term `genetic screening’ has been used for decades, this paper discusses how, 
in its most precise meaning, genetic screening has not yet been widely introduced. `Prenatal 
screening’ is often confused with `genetic screening’. As we show, these terms have 
different meanings, and we examine definitions of the relevant concepts in order to illustrate 
this point. The concepts are (I) prenatal (ii) genetic screening (iii) screening, scanning and 
testing (iv) maternal and foetal tests (v) test techniques and (vi) genetic conditions. So far, 
prenatal screening has little connection with precisely defined genetics. There are benefits but 
also disadvantages in overstating current links between them in the term genetic screening. 
Policy making and professional and public understandings about screening could be clarified 
if the distinct meanings of prenatal screening and genetic screening were more precisely 
observed.   
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Introduction 
The phrase `genetic screening’ has been used for approximately 20 years.(1-4) This paper 
argues that genetic screening, in its most precise definition, has not yet begun to be used 
widely, although it is often discussed as if it is already in common use. The language has long 
preceded the practice and one reason for this is confusion between prenatal screening and 
genetics screening. Yet, so far, prenatal screening in many European countries has little to do 
with the new genetics. During our European research project, we discussed the use of key 
terms across different cultures, languages and disciplines. The concepts are (I) prenatal (ii) 
genetic screening (iii) screening, scanning and testing (iv) maternal and foetal tests (v) test 
techniques and (vi) genetic conditions. Our discussions are summarised in this paper in order 
to clarify differences between genetic and prenatal screening. We conclude that premature use 
of the term genetic screening opens the way for prenatal screening to become genetic without 
debate about whether societies, practitioners and prospective parents wish to make this step 
 
Prenatal  
Prenatal generally means `pregnancy up to birth'. Yet it can include the pre-conceptual period 
in relation, for example, to advice about smoking, alcohol and folic acid. The >couple 
forming’ stage involves prenatal considerations, such as when testing for thalassaemia or Tay 
Sachs among certain ethnic groups. Prenatal can be stretched to cover any stage of life when 
people are tested for their genetic carrier status in order to inform future family planning by 
themselves or their relatives.(3-6) 
 
Genetic conditions  
Genetic conditions include the following.  
(I) A heritable condition determined by a single gene that is recessive (for example, cystic 
fibrosis or aspartylglucosaminuria (AGU) in Finland) or dominant (Huntington’s chorea) or 
is linked to sex chromosome genes (haemophilia).  
(Ii) A congenital condition due to prenatal environmental effects on genes or chromosomes, 
but not showing clear Mendelian heritance and so not genetic in a narrow sense, such as, 
chromosomal disorders (Down’s syndrome) or neural tube, organ and limb disorders.  
(Iii) A condition which develops postnatally when a polygenic predisposition interacts with 
the environment (diabetes, cancer and, possibly, some behaviours) and which is also not 
strictly genetic.  
 
Genetic screening   
The Nuffield Report (3) divides genetic screening into tests for single gene disorders, 
polygenic disorders, and chromosomal conditions. Yet these conditions are either not 
commonly screened for prenatally or are not precisely genetic.  
 
Prenatal screening   
Screening is the systematic search for a specific condition among a large, asymptomatic 
subpopulation selected by demographic characteristics such as age, sex or ethnicity. 
Screening typically identifies at-risk groups for further diagnostic testing. Routine maternal 
screening, for age, weight, blood pressure, rhesus factor, syphilis, HIV and diabetes can be 
used to promote maternal, and thereby foetal, health. Screening for foetal conditions does not 
exactly fit the World Health Organisation (WHO) principles (7) and, so far, collects only 
partial and indirect evidence of probabilities through the parents’ carrier status or through 
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maternal blood samples. As the screening does not directly access the fetus, the tests are not 
highly reliable. The main available >treatment’ and methods of >improving’ the natural 
history are through termination of pregnancy. 
   Mass screening overlaps with diagnostic testing when tests such as amniocentesis or 
chorionic villus sampling (CVS) are routinely offered as initial rather than follow-up checks, 
and offered to asymptomatic subpopulations such as women aged over 35 years. 
 
Prenatal testing   
More precise diagnostic testing is possible when material associated with the fetus is obtained 
through amniocentesis or CVS. Because the tests are invasive and expensive and incur high 
maternal anxiety and the risk of miscarriage (8-11) they are generally offered to selected 
individuals after initial screening (such as of maternal serum) shows them to be a higher risk. 
  Tests can be classified by the evidence examined and the techniques used. The evidence is 
either the genotype (DNA) or the phenotype (how the condition expresses itself in anatomy, 
biochemistry, bodily functions or behaviours) which include the following.   
(I) Molecular chromosomal tests (cytogenetics). 
(ii) Single gene disorder tests which, because genes are invisible, test for proteins which the 
gene produces, or else genetic markers which indicate the position of the gene on the 
chromosome. 
(iii) Biochemical tests, such as of hormonal changes in maternal serum possibly in response 
to a foetal condition. 
(iv) Ultrasound scanning of the fetus. 
To our knowledge, at present in Europe, no prenatal mass screening is strictly genetic in the 
sense of examining genotypes in a genetic laboratory. Single gene conditions subjected to 
carrier screening such as thalassaemia are tested for phenotypes in haematology laboratories. 
Serum screening for Down’s syndrome and neural tube defects, which are not strictly genetic 
conditions, involves biochemical markers not DNA or DNA tests. Single gene conditions, 
which are investigated by DNA tests, are so far not routinely screened for, although this is 
likely to change if researchers succeed in isolating foetal blood from maternal blood samples. 
 
Prenatal scanning 
Prenatal scanning, ultrasound, blurs differences between screening of large asymptomatic 
groups and diagnostic testing of individuals. As unfocused screening, scanning detects 
hundreds of anomalies. Scanning fits few of the WHO screening criteria,(7) which are clearer 
than more recently proposed criteria.(12-13) So far, the more common, serious and single 
gene disorders such as cystic fibrosis and haemoglobinopathies have not been clearly linked 
to features that can be detected by scans and may not have such features.    
  Scanning is too routinely used with large asymptomatic groups to count as individual 
testing, but the investigations are often too varied, individual, specifically diagnostic or linked 
to rare conditions to count as mass screening. The process of scanning would classify it as 
screening, but the outcomes of scanning would often classify it as testing (see table 1). 
 
Discussion 
So far, prenatal genetic screening, in the precise sense of mass screening of asymptomatic 
groups for heritable genetic conditions confirmed by DNA analysis during pregnancy, does 
not yet occur in Europe. So why have prenatal and genetic screening been linked for two 
decades? (Refs 1-4) The advantages of such associations for prenatal screening and scanning 
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are that `genetics’ attracts public interest and respect, funding and prestigious associations 
with scientific progress and precise diagnosis. 
  The disadvantages are that overuse of the word genetics could be alarmist and often 
inaccurate.(12, 14) It can divert attention from the way social, psychological and economic 
conditions increase or reduce congenital disabilities and how `the notion that health or illness 
can be predicted on the basis of DNA patterns becomes highly questionable’. (15) To present 
choices in terms of genetics can inadvertently make prospective parents feel ignorant and 
dependent on experts for guiding their decision making. (16, 17) Scanning further 
complicates consent because of the great range of possible conditions the scan may 
unexpectedly reveal. (18) Assumptions that genetics means Mendelian heritance patterns can 
increase fears misleadingly (I) into worries about a kind of family infection or inadequacy (ii) 
into guilt when parents feel they should somehow  predict and prevent affected births and (iii) 
into an implied or explicit overemphasis on biological determinism which can undermine 
confidence in human agency and social opportunities.(19) These trends are likely to 
encourage people to reduce their thinking about prenatal questions to terms of medical 
problems and solutions, the most immediate solution being termination of pregnancy. 
  Except for thalassaemia and sickle cell in some areas, the big step of introducing routine 
single gene prenatal screening has not yet been made. Attempts to screen for AGU in Finland 
were interrupted as impractical and unethical.(20) Talk of prenatal screening as if it is already 
genetic opens the way for it to become so without debate about whether society wishes to 
make this step. Discussion which links genetics to prenatal screening and scanning could 
misinform people who receive, plan and provide these services instead of clarifying their 
informed, unpressured decision making.  
 
The study was funded by the European Commission Biomed II, project no. BMH4-CT96-
0740, Prenatal Screening in Europe: Past, Present and Future.  
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Table 1. Types of prenatal conditions, screening and tests 
 
Types of tests   of genotypes  of phenotypes 
  DNA   biochemistry anatomy/function history  
from:  amnio   blood  amnio blood scan observation/ interview 
/cvs   /cvs 
subject: foetal parental foetal parental  foetal parental family 
Examples of  
prenatal conditions/ 
maternal health 
 
Environment and  
maternal health          s  s 
age, diet, weight          s 
smoking alcohol          s 
infection         s  
hypertension           s  
diabetes (urine)        s 
 
Environment and 
polygenic effects 
neural tube,      t    s       u      s 
organ and limb     t    s       u   s    
disorders 
 
Chromosomal 
Trisomy 13, 21    t    s        u   s 
 
Single gene 
cystic fibrosis  t  t      s 
thalassaemia.    t t     s 
sickle cell,     t t     s 
fragile X  t  t      s  
AGU   t  t      s 
 
s - screening, t - testing, u - ultrasound scanning 
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